# A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

> **NCT04658199** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 19 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** UCB0107 (bepranemab)

## Key facts

- **NCT ID:** NCT04658199
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-16
- **Primary completion:** 2027-12-13
- **Final completion:** 2027-12-13
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04658199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04658199, "A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04658199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*